HAPPENING NOW
Health · 1 views
FDA expands use of Zoryve to include young children with plaque psoriasis
The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment…
AI Summary
The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of plaque psoriasis in patients ages 2 and older. The expanded approval was granted to Arcutis Biotherapeutics.
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNowMore from Health
Continue reading recent Health coverage